WARCEF - Warfarn vs. Aspirin in Reduced Cardiac Ejection Fraction

WARCEF - Warfarn vs. Aspirin in Reduced Cardiac Ejection Fraction. Includes Change in Eligibility Criteria (Eligibility Ejection Fraction Has Been Increased From less than 30 to less than 35%) To compare the efficacy and safety of Warfarin (INR 2.0-3.0) with aspirin (325 mg per day) for preventing all-cause mortality and disability in patients with cardiac EF less than 35%.
NIH 683
Neurology (Brain & Nerve)
W. Scott Burgin, MD
Open
Cheryl Weber, RN, MS, CCRC
585-922-4111
585-922-4371